• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Neumora Therapeutics Inc.

    5/30/25 5:21:01 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NMRA alert in real time by email
    8-K
    false 0001885522 0001885522 2025-05-28 2025-05-28
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 28, 2025

     

     

    NEUMORA THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-41802   84-4367680

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification Number)

     

    490 Arsenal Way, Suite 200

    Watertown, Massachusetts

      02472
    (Address of principal executive offices)   (Zip Code)

    (857) 760-0900

    (Registrant’s telephone number, including area code)

    N/A

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, $0.0001 par value per share   NMRA   The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    On May 28, 2025, Neumora Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on four proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2025 (the “Definitive Proxy Statement”). Only stockholders of record as of the close of business on April 28, 2025, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 161,747,922 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:

    Proposal 1. The election of two Class II directors to hold office until the 2028 annual meeting of stockholders and until their respective successor is elected and qualified or until their earlier death, resignation, disqualification or removal. The results of the vote were as follows:

     

    Nominee

       Votes For      Votes Withheld      Broker
    Non-Votes
     

    Alaa Halawa

         105,795,914        10,483,889        19,873,065  

    Maykin Ho, Ph.D.

         114,262,481        2,017,322        19,873,065  

    Proposal 2. The ratification of the selection by the audit committee of the board of directors of the Company (the “Board”) of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025. The results of the vote were as follows:

     

    Votes For

      

    Votes Against

      

    Abstentions

    135,734,870    362,316    55,682

    As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.

    Proposal 3. The approval of the repricing of certain outstanding stock options that have been granted under the Company’s 2020 Equity Incentive Plan and 2023 Incentive Award Plan. The results of the vote were as follows:

     

    Votes For

      

    Votes Against

      

    Abstentions

      

    Broker Non-Votes

    101,589,422    14,632,276    58,105    101,589,422

    Proposal 4. The approval of amendments to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio ranging from any whole number between 1-for-5 and 1-for-30, as determined by the Board in its discretion. The results of the vote were as follows:

     

    Votes For

      

    Votes Against

      

    Abstentions

    134,256,461    1,892,564    55,682

    As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        NEUMORA THERAPEUTICS, INC.
    Date: May 30, 2025     By:  

    /s/ Michael Milligan

          Michael Milligan
          Chief Financial Officer
    Get the next $NMRA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NMRA

    DatePrice TargetRatingAnalyst
    4/2/2025$1.00Buy → Underperform
    BofA Securities
    3/10/2025Outperform → Mkt Perform
    William Blair
    3/7/2025Buy → Neutral
    Guggenheim
    3/7/2025$6.00 → $2.00Buy → Hold
    Stifel
    1/2/2025$29.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    11/5/2024$18.00 → $15.00Overweight → Neutral
    JP Morgan
    10/1/2024$30.00Buy
    H.C. Wainwright
    7/22/2024$23.00Buy
    Needham
    More analyst ratings

    $NMRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      On track to report topline data from NMRA-511 in Alzheimer's disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Expect to progress M4 positive allosteric modulator (PAM) program into the clinic in mid-2025 Secured $125 million venture debt facility from K2 HealthVentures, with $40 million available in 2025; cash runway extended into 2027 Company to host conference call today at 4:30 p.m. ET WATERTOWN, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-s

      5/12/25 4:01:00 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Monday, May 12, 2025 to report its first quarter 2025 financial results and provide a business update. A live webcast of the event will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Part

      4/28/25 7:00:00 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Galapagos Announces Executive Leadership Updates

      Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo  Dr. Paul Stoffels, Chair and CEO of Galapagos, plans to retire as CEO upon appointment of successor in the next 12 months and plans to continue as Chair of the Board of Directors, ensuring leadership continuity and long-term strategic guidance Mechelen, Belgium; April 21, 2025, 22:10 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today makes two executive leadership announcements. In line with its planned separation

      4/21/25 4:10:00 PM ET
      $GLPG
      $NMRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $NMRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Neumora Therapeutics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Neumora Therapeutics from Buy to Underperform and set a new price target of $1.00

      4/2/25 8:47:48 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neumora Therapeutics downgraded by William Blair

      William Blair downgraded Neumora Therapeutics from Outperform to Mkt Perform

      3/10/25 7:56:32 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neumora Therapeutics downgraded by Guggenheim

      Guggenheim downgraded Neumora Therapeutics from Buy to Neutral

      3/7/25 8:22:06 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Officer Milligan Michael Lee

      4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

      5/30/25 6:31:14 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Fust Matthew K

      4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

      5/30/25 6:30:51 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Officer Duncan Jason

      4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

      5/30/25 6:30:59 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NMRA
    SEC Filings

    See more
    • SEC Form 8-K filed by Neumora Therapeutics Inc.

      8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)

      5/30/25 5:21:01 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Neumora Therapeutics Inc.

      DEFA14A - Neumora Therapeutics, Inc. (0001885522) (Filer)

      5/16/25 4:28:34 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Neumora Therapeutics Inc.

      8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)

      5/16/25 4:26:52 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NMRA
    Financials

    Live finance-specific insights

    See more
    • Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      On track to report topline data from NMRA-511 in Alzheimer's disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Expect to progress M4 positive allosteric modulator (PAM) program into the clinic in mid-2025 Secured $125 million venture debt facility from K2 HealthVentures, with $40 million available in 2025; cash runway extended into 2027 Company to host conference call today at 4:30 p.m. ET WATERTOWN, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-s

      5/12/25 4:01:00 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Monday, May 12, 2025 to report its first quarter 2025 financial results and provide a business update. A live webcast of the event will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Part

      4/28/25 7:00:00 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neumora Therapeutics Announces Leadership Transition

      Paul L. Berns, executive chair of Neumora Board of Directors, to serve as chief executive officer and chairman of the Board Joshua Pinto, Ph.D. to serve as president Bill Aurora, Pharm.D. to serve as chief operating and development officer; Michael Milligan to serve as chief financial officer Neumora to host conference call on March 3, 2025 to report its fourth quarter and full year 2024 financial results and provide a business update WATERTOWN, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced th

      2/13/25 7:00:00 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NMRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

      On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of 2024 and Phase 1 data with NMRA-266 in healthy adult participants mid-2024 Strong financial position with $463.8 million in cash, cash equivalents and marketable securities expected to support operations into 2026 WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update. "2023 was a watershed year for Neumora as we

      3/7/24 7:00:00 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer

      WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora's executive team, reporting to Henry Gosebruch, president and chief executive officer. Ms. Pai Panandiker has more than 20 years of experience commercializing medicines in areas of significant unmet need, including the commercial launches of TRINTELLIX® (vortioxetine) and REXULTI® (brexpiprazole) for major depressive disorder (MDD) and schizophrenia. "I am excited to welcome Kaya to Neumora. As we progress t

      1/22/24 7:00:00 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer

      WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Jason Duncan as chief legal officer. Mr. Duncan will be a member of Neumora's Executive Team, reporting to Henry Gosebruch, chief executive officer, and will oversee all aspects of the Company's legal and compliance functions. "I am pleased to welcome Jason to Neumora. With his unique background that combines legal expertise with program strategy, I am confident that he will be a valuable addition to our team as we seek to deliver on our mission to redefine neuroscience drug dev

      12/12/23 7:00:00 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Neumora Therapeutics Inc.

      SC 13D/A - Neumora Therapeutics, Inc. (0001885522) (Subject)

      11/22/24 5:33:43 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Neumora Therapeutics Inc.

      SC 13G - Neumora Therapeutics, Inc. (0001885522) (Subject)

      11/12/24 4:30:30 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care